Journal
NEURODEGENERATIVE DISEASE MANAGEMENT
Volume 8, Issue 2, Pages 97-103Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/nmt-2017-0047
Keywords
claims database; comorbidity; Japan; multiple sclerosis; prevalence; treatment
Categories
Funding
- Takeda Pharmaceutical Company Ltd.
Ask authors/readers for more resources
Aim: Use real-world data to investigate the treatment, comorbidities and prevalence of multiple sclerosis (MS) in an employed Japanese population. Methods: Data from the Japanese Medical Data Center health insurance claims database were analyzed (January 2005-November 2014). Patients with claims associated with an MS diagnosis were identified (n = 494) and comorbidities and prescribed treatments were investigated. MS prevalence within the database was calculated for each calendar year (2011-2013) Results: IFN-beta and prednisolone were the most commonly prescribed treatments. Common comorbidities included astigmatism and gastric ulcer. Within the database, MS prevalence increased from 0.015 to 0.016%. Conclusion: MS prevalence increased from 2011 to 2013. Some comorbidities were considered unrelated to MS owing to how physicians use disease codes for reimbursement.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available